MiR-221-3p Facilitates Thyroid Cancer Cell Proliferation and Inhibit Apoptosis by Targeting FOXP2 Through Hedgehog Pathway
- PMID: 35257310
- DOI: 10.1007/s12033-022-00473-5
MiR-221-3p Facilitates Thyroid Cancer Cell Proliferation and Inhibit Apoptosis by Targeting FOXP2 Through Hedgehog Pathway
Abstract
Thyroid cancer (TC) is most often found in the endocrine system, the incidence of which has been on a continuous increase in recent years. For a better treatment of it, it becomes a pressing matter to further delve into the mechanism of TC onset and progression. FOXP2 is lowly expressed in diverse cancer, which has a deep connection with malignant progression of tumors. However, in TC, studies about this gene are exceedingly limited. In this study, FOXP2 was discovered to be lowly expressed in TC tissues based on the analysis of TCGA database. This finding was further confirmed by the qRT-PCR that FOXP2 was lowly expressed in TC cell lines. The results of a series of cell function assays demonstrated that overexpressed FOXP2 could hamper TC cell proliferation and stemness, facilitate apoptosis, and arrest the cell cycle. For a deep exploration of its mechanism, we mined its upstream factor miR-221-3p with the aid of starBase and mirDIP databases. The dual-luciferase reporter assay was employed to verify the binding relationship between miR-221-3p and FOXP2. Besides, we also discovered the HEDGEHOG pathway existing downstream of FOXP2 by gene set enrichment analysis. Based on these findings, we also performed a rescue experiment, the result of which indicated that the overexpression of FOXP2 was able to reverse the effects of overexpressed miR-221-3p in several cell activities including proliferation, sphere-formation, apoptosis, and cell cycle. Besides, it could also have an impact on the expression of HEDGEHOG pathway-related proteins influenced by overexpressed miR-221-3p. Our study provided the new insights into the mechanism by which miR-221-3p functions in the development of TC.
Keywords: Apoptosis; FOXP2; Proliferation; Thyroid cancer; miR-221-3p.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
MiR-299-3p functions as a tumor suppressor in thyroid cancer by regulating SHOC2.Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):232-240. doi: 10.26355/eurrev_201901_16769. Eur Rev Med Pharmacol Sci. 2019. PMID: 30657565
-
miR-196a-2 Promotes Malignant Progression of Thyroid Carcinoma by Targeting NRXN1.Comput Math Methods Med. 2021 May 31;2021:4856820. doi: 10.1155/2021/4856820. eCollection 2021. Comput Math Methods Med. 2021. Retraction in: Comput Math Methods Med. 2023 Sep 27;2023:9827094. doi: 10.1155/2023/9827094. PMID: 34158819 Free PMC article. Retracted.
-
Hsa_circ_0043265 Suppresses Proliferation, Metastasis, EMT and Promotes Apoptosis in Non-Small Cell Lung Cancer Through miR-25-3p/FOXP2 Pathway.Onco Targets Ther. 2020 May 7;13:3867-3880. doi: 10.2147/OTT.S235231. eCollection 2020. Onco Targets Ther. 2020. PMID: 32440153 Free PMC article.
-
Sexual dimorphism in thyroid cancer: evidence from preclinical studies.Endocr Relat Cancer. 2025 Apr 22;32(5):e240348. doi: 10.1530/ERC-24-0348. Print 2025 May 1. Endocr Relat Cancer. 2025. PMID: 40197424 Review.
-
The untold stories of the speech gene, the FOXP2 cancer gene.Genes Cancer. 2018 Jan;9(1-2):11-38. doi: 10.18632/genesandcancer.169. Genes Cancer. 2018. PMID: 29725501 Free PMC article. Review.
Cited by
-
FOXP2 mediates ZSCAN18 transcriptional activation to inhibit oral squamous cell carcinoma progression by blocking Hedgehog signaling.Mamm Genome. 2025 Jun 24. doi: 10.1007/s00335-025-10147-7. Online ahead of print. Mamm Genome. 2025. PMID: 40555855
-
MiRNAs in Extracellular Vesicles as Biomarkers in Plasma of Papillary Thyroid Cancer Patients: A Proof-of-Concept Study.Biology (Basel). 2024 Sep 22;13(9):743. doi: 10.3390/biology13090743. Biology (Basel). 2024. PMID: 39336170 Free PMC article.
-
Tubular FoxP2 and Kidney Fibrosis.J Am Soc Nephrol. 2025 Apr 1;36(4):544-558. doi: 10.1681/ASN.0000000576. Epub 2024 Dec 10. J Am Soc Nephrol. 2025. PMID: 39656554
-
Profilin1 Promotes Renal Tubular Epithelial Cell Apoptosis in Diabetic Nephropathy Through the Hedgehog Signaling Pathway.Diabetes Metab Syndr Obes. 2023 Jun 9;16:1731-1743. doi: 10.2147/DMSO.S411781. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 37323855 Free PMC article.
-
Hedgehog pathway and cancer: A new area (Review).Oncol Rep. 2024 Sep;52(3):116. doi: 10.3892/or.2024.8775. Epub 2024 Jul 12. Oncol Rep. 2024. PMID: 38994763 Free PMC article. Review.
References
-
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394–424. https://doi.org/10.3322/caac.21492 - DOI
-
- Ren, R., Du, Y., Niu, X., & Zang, R. (2021). ZFPM2-AS1 transcriptionally mediated by STAT1 regulates thyroid cancer cell growth, migration and invasion via miR-515-5p/TUSC3. Journal of Cancer, 12, 3393–3406. https://doi.org/10.7150/jca.51437 - DOI - PubMed - PMC
-
- Jin, M., Lee, W. K., You, M. H., Jang, A., Cheng, S. Y., Kim, W. G., Jeon, M. J., & Lee, Y. M. (2021). SHMT2 expression as a diagnostic and prognostic marker for thyroid cancer. Endocrine Connections, 10, 630–636. https://doi.org/10.1530/EC-21-0135 - DOI - PubMed - PMC
-
- Wang, L., Huang, Y., Liu, C., Guo, M., Ma, Z., He, J., Wang, A., Sun, X., & Liu, Z. (2021). Deltex3 inhibits epithelial mesenchymal transition in papillary thyroid carcinoma via promoting ubiquitination of XRCC5 to regulate the AKT signal pathway. Journal of Cancer, 12, 860–873. https://doi.org/10.7150/jca.48141 - DOI - PubMed - PMC
-
- Luo, Q., Guo, F., Fu, Q., & Sui, G. (2021). hsa_circ_0001018 promotes papillary thyroid cancer by facilitating cell survival, invasion, G1/S cell cycle progression, and repressing cell apoptosis via crosstalk with miR-338-3p and SOX4. Molecular Therapy—Nucleic Acids, 24, 591–609. https://doi.org/10.1016/j.omtn.2021.02.023 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical